GetTopicDetailResponse(id=fe7f2346eb, topicName=Alpelisib, introduction=Alpelisib, content=null, image=null, comments=4, allHits=1052, url=https://h5.medsci.cn/topic?id=2346, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=70198, tagList=[TagDto(tagId=70198, tagName=Alpelisib)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1605245, encodeId=affc16052454b, content=<a href='/topic/show?id=fe7f2346eb' target=_blank style='color:#2F92EE;'>#Alpelisib#</a>, objectTitle=Clin Cancer Res：口服選擇性雌激素受體降解劑±Ribociclib或Alpelisib治療ER+乳腺癌的療效和安全性, objectType=article, longId=216493, objectId=e168216493b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e168216493b8, replyNumber=0, likeNumber=93, createdTime=2021-09-01, rootId=0, userName=12498561m38(暫無昵稱), userId=859419357438, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e168216493b8, moduleTitle=Clin Cancer Res：口服選擇性雌激素受體降解劑±Ribociclib或Alpelisib治療ER+乳腺癌的療效和安全性, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=e168216493b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1605244, encodeId=c03f1605244fe, content=<a href='/topic/show?id=fe7f2346eb' target=_blank style='color:#2F92EE;'>#Alpelisib#</a>, objectTitle=Clin Cancer Res：Alpelisib聯(lián)合曲妥珠單抗和LJM716治療PIK3CA突變的HER2陽性轉(zhuǎn)移性乳腺癌, objectType=article, longId=214659, objectId=4cc12146596f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4cc12146596f, replyNumber=0, likeNumber=84, createdTime=2021-07-24, rootId=0, userName=12498561m38(暫無昵稱), userId=859419357438, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4cc12146596f, moduleTitle=Clin Cancer Res：Alpelisib聯(lián)合曲妥珠單抗和LJM716治療PIK3CA突變的HER2陽性轉(zhuǎn)移性乳腺癌, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=4cc12146596f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1605243, encodeId=078a160524305, content=<a href='/topic/show?id=fe7f2346eb' target=_blank style='color:#2F92EE;'>#Alpelisib#</a>, objectTitle=Ann Oncol：Alpelisib+氟維司群治療PIK3CA突變型HR+HER2-晚期乳腺癌的療效, objectType=article, longId=205897, objectId=fcad20589ed6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcad20589ed6, replyNumber=0, likeNumber=93, createdTime=2021-01-21, rootId=0, userName=12498561m38(暫無昵稱), userId=859419357438, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcad20589ed6, moduleTitle=Ann Oncol：Alpelisib+氟維司群治療PIK3CA突變型HR+HER2-晚期乳腺癌的療效, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=fcad20589ed6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1605242, encodeId=c94b1605242fc, content=<a href='/topic/show?id=fe7f2346eb' target=_blank style='color:#2F92EE;'>#Alpelisib#</a>, objectTitle=**乳腺癌PI3K抑制劑Alpelisib上市，諾華開啟乳腺癌分子分型新時(shí)代, objectType=article, longId=177001, objectId=9f851e70016d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f851e70016d, replyNumber=0, likeNumber=97, createdTime=2019-08-07, rootId=0, userName=12498561m38(暫無昵稱), userId=859419357438, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f851e70016d, moduleTitle=**乳腺癌PI3K抑制劑Alpelisib上市，諾華開啟乳腺癌分子分型新時(shí)代, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=9f851e70016d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
